不应忽视未来:纳入未来成本对荷兰成人PCV13肺炎球菌结合疫苗成本效果的影响
该研究更新了荷兰成人接种13价肺炎球菌结合疫苗(PCV13)的成本效果分析,纳入未来医疗与非医疗成本。结果显示,基础情景ICER为每QALY 9157欧元,纳入全部未来医疗成本后升至28540欧元,再纳入未来非医疗成本后为45691欧元;未来医疗成本的影响随年龄和风险组而异。
要点
- 纳入未来医疗成本使PCV13成人接种的ICER从每QALY 9157欧元升至28540欧元。
- 进一步纳入未来非医疗成本后,ICER为每QALY 45691欧元。
- 未来医疗成本的影响因风险组而异,且通常随年龄增加而增大。
核心结论
- 纳入未来成本对PCV13成人接种的ICER有显著影响,可能使疫苗接种相对低预防阈值而言吸引力下降。
- 忽视真实的未来成本可能导致医疗资源使用效率低下,结果提示部分疫苗价格可能需要降低才具成本效果。
研究设计与样本
- 更新现有荷兰成人PCV13接种成本效果分析,纳入全部未来医疗与非医疗成本。
- 按年龄和风险将成本与生存信息及原研究各接种策略的预防病例数估计相链接。
- 未来医疗成本按相关风险组进行调整。
主要发现
- 基础情景策略下PCV13原始ICER为每QALY 9157欧元。
- 纳入全部未来医疗成本后ICER升至每QALY 28540欧元。
- 同时纳入未来非医疗成本后ICER为每QALY 45691欧元。
- 未来医疗成本的影响因风险组而异,且通常随年龄增加而增大。
- 当有基础健康问题者生命延长时,未来医疗成本的影响较大。
临床怎么用
- 在疫苗成本效果分析中应考虑纳入未来医疗与非医疗成本,并按风险组区分成本估计。
- 解读ICER时需注意是否纳入未来成本,尤其涉及有基础疾病人群生命延长时。
- 决策时应权衡未来成本纳入对预防阈值判断及疫苗定价的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: When vaccines increase longevity, vaccinated people may experience costs and benefits during added life-years. These future benefits and costs may include increased productivity as well as medical and non-medical costs. Such impacts should be considered in cost-effectiveness analyses (CEA) of vaccines but are often omitted. Here, we illustrate the impact of including future costs on the cost-effectiveness of vaccination against pneumococcus disease. We emphasize the relevance of differentiating cost estimates between risk groups. METHODS: We updated an existing Dutch CEA of vaccination against pneumococcus disease with the 13-valent pneumococcal conjugate vaccine (PCV13) to include all future medical and non-medical costs. We linked costs by age and risk with survival information and estimates of cases prevented per vaccination strategy based on the original study to calculate the impact of inclusion. Future medical costs were adjusted for relevant risk groups. RESULTS: For the base-case strategy, the original incremental cost-effectiveness ratio (ICER) of PVC13 was €9,157 per quality adjusted life-year (QALY). Including all future medical costs increased the ICER to €28,540 per QALY. Also including future non-medical costs resulted in an ICER of €45,691 per QALY. The impact of future medical costs varied considerably per risk group and generally increased with age. DISCUSSION AND CONCLUSION: This study showed a substantial effect of the inclusion of future costs on the ICER of vaccinating with PCV13. Especially when lives of people with underlying health conditions are extended, the impact of future medical costs is large. This inclusion may make vaccination a less attractive option, especially in relation to low thresholds as often applied for prevention. Although this raises important questions, ignoring these real future costs may lead to an inefficient use of healthcare resources. Our results may imply that prices for some vaccines need to be lowered to be cost-effective.
引用
- de Vries LM, Kellerborg KM, Brouwer WBF, et al. Don't forget about the future: The impact of including future costs on the cost-effectiveness of adult pneumococcal conjugate vaccination with PCV13 in the Netherlands. Vaccine. 2021. PMID: 34116878. doi:10.1016/j.vaccine.2021.05.091
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。